This Month in Psychopharmacology

Erectile Dysfunction Drugs May Protect Against Alzheimer’s

With Alzheimer’s disease (AD) cases projected to reach 157 million ...

Read More

Blood Test Predicts Who Might Benefit Most From Anti-Amyloid Drugs

The widely accepted Amyloid Cascade Hypothesis indicates that the m...

Read More

Gut Microbiome Composition May be an Indicator of Preclinical Alzheimer’s Disease

With Alzheimer’s disease (AD) becoming a global crisis, as lifespan...

Read More

Sleep-Disordered Breathing Tied to Brain Volumes in Amyloid-Positive Older Adults

Sleep-disordered breathing (SDB) has been associated with increased...

Read More

FDA Approves First Treatment for Agitation Associated with Alzheimer’s Dementia

The U.S. Food and Drug Administration (FDA) has approved the supple...

Read More

Blood Test Predicts Which People With Amyloid Are Likely to Decline Cognitively

The pathology of Alzheimer’s disease (AD) begins with a prolonged p...

Read More

The Future of Psychopharmacology

It is an incredible time in terms of the development of new psychop...

Read More

FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment

The U.S. Food and Drug Administration recently approved lecanemab, ...

Read More

'Convincing Evidence' Hearing Aids Reduce Dementia Risk

With no truly effective treatment for dementia yet available, there...

Read More

Highlights from 2022 NEI Congress: Management of Agitation Associated With Alzheimer’s Dementia

When a patient presents with agitation it represents a substantial ...

Read More

Alzheimer's Awareness Month

October is ADHD Awareness Month. The goal of ADHD Awareness Month i...

Read More

FDA Panel Rejects Pimavanserin for Alzheimer's Psychosis

A U.S. Food and Drug Administration advisory panel voted 9:3 agains...

Read More